Developer of nanomedical platform for treating major human and animal diseases. Its products remove the molecular signals or signal inhibitors that assist disease progression and are later cleared from the body via phagocytosis. It has features including nanoparticles made of biocompatible materials, the inclusion of a binding-capture agent, and the shielding of the capture agent with cell membrane receptors. Founded in 2015, headquartered in Mill Valley, United States. The company has raised $10M at the Series A stage backed by investors including LifeSpan Vision Ventures, HHS, Lauder Partners, quadraScope, Melnichek Investments. Operating in Life Sciences > Oncology, Life Sciences > Drug Delivery.
← All startups
NaNotics
Series ADeveloper of nanomedical platform for treating major human and animal diseases. Its products remove the molecular signals or signal inhibitors that assist disease progression and are later cleared from the body via phagocytosis. It has features including nanoparticles made of biocompatible materials, the inclusion of a binding-capture agent, and the shielding of the capture agent with cell membrane receptors.…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Encapsulation,
Oncology > Drugs > Diversified,
Drug Delivery > Nanoparticle Based
Institutional investors
LifeSpan Vision VenturesHHSLauder PartnersquadraScopeMelnichek Investments
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
🗂️ Full list of active funds — filter by stage, check size, and geography.